• 1
    Dravet C, Bureau M, Guerrini G, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: RogerJ, BureauM, DravetC, DreifussFE, PerretA, WolfP, eds. Epileptic syndromes in infancy, childhood and adolescence. London : John Libbey, 1992: 7588.
  • 2
    Guerrini R, Dravet C. Severe epileptic encephalopathies of infancy, other than West syndrome. In: EngelJ, PedleyTA, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott-Raven, 1997:2285302.
  • 3
    Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46:15276.
  • 4
    Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:9917.
  • 5
    Bartoli A, Guerrini R, Belmonte A, Alessandri MG, Gatti G, Perucca E. The influence of dosage, age, and comedication on steady-state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997;19:1007.
  • 6
    Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994;344:13756.
  • 7
    Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in the treatment of 120 children with epilepsy. Epilepsia 1994;35:35967.
  • 8
    Oller LFV, Russi A, Daurella L. Lamotrigine in Lennox-Gastaut syndrome. Epilepsia 1991;31(suppl 1):58.
  • 9
    Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992;32:3057.
  • 10
    Mullens L, Gallagher J, Manasco P. for The Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational placebo-controlled trial. Epilepsia 1996;37(suppl 5):163.
  • 11
    Billard C, Motte J, Arvidsson D, et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia 1996;37(suppl 4):92.
  • 12
    Genton P, Dravet C, Bureau N, Formosa F, Mesdjian E. Aggravation of severe myoclonic epilepsy of infants by lamotrigine. Epilepsia 1997;38(suppl 3):32.
  • 13
    Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 1996;94:36777.
  • 14
    Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia (in press).
  • 15
    Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 1986;2:3405.
  • 16
    Wakai S, Ito N, Sucoka H, Kawamoto Y, Hayasa H, Chiba S. Severe myoclonic epilepsy in infancy and carbamazepine. Eur J Pediatr 1996;155:724.
  • 17
    Ahnut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B, for the International Gabapentin Study Group. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35:795801.
  • 18
    Genton P, Guerrini R, Roger J. Treatment of epilepsy in children and adults with multiple handicaps. In: ShorvonS, DreifussF, FishD, ThomasD, eds. The treatment of epilepsy. London : Blackwell Science, 1996:21526.
  • 19
    Sander JWAS, Hart YM, Patsalos PN, Duncan JS, Shorvon SD. Lamotrigine and generalized seizures. Epilepsia 1991;32(suppl 1): 59.
  • 20
    Gibbs J, Appleton RE, Rosenbloom L, Yuen WC. Lamotrigine for intractable childhood epilepsy: a preliminary communication. Dev Med Child Neurol 1992;34:36871.
  • 21
    Timmings PL, Richens A. Efficacy of lamotrigine as monotherapy for juvenile myoclonic epilepsy: pilot study results. Epilepsia 1993;34(suppl 2):160.
  • 22
    Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. LTG as add-on drug in typical absence seizures. Acta Neurol Scand 1994; 91:2002.
  • 23
    Renier WO, Renkawek K. Clinical and neuropathological findings in a case of severe myoclonic epilepsy of infancy. Epilepsia 1990; 31:28791.
  • 24
    Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996;42:5313.
  • 25
    Dalla Bernardina B, Capovilla B, Gattoni G, et al. Epilepsie myoclonique grave de la premiére année. Rev EEG Neurophysiol 1982; 1295.
  • 26
    Dulac O, Arthuis M. L'épilepsie myoclonique sévère de l'enfant. In: Journées parisiennes de pédiatrie. Paris : Flammarion, 1982: 25968.
  • 27
    Ogino T, Ohtsuka Y, Yamatogi Y, Oka E, Ohtahara S. Severe, myoclonic epilepsy in infancy: clinico-electroencephalographic and long-term follow up studies. Brain Dev 1986;8:162.
  • 28
    Sugama M, Oguni H, Fukuyama Y. Clinical and electroencephalographic study of severe myoclonic epilepsy in infancy. Jin J Psychiatr Neurol 1987;41:4635.
  • 29
    Hurst DL. Severe myoclonic epilepsy in infancy. Pediatr Neurol 1987;3:26972.
  • 30
    Musumeci SA, Elia M, Ferri R, et al. Epilessia mioclonica grave in due gemelli monozigoti con sindrome di Rud. Boll Lega Ital Epil 1992;79/80:81–2.
  • 31
    Fujiwara T, Nakamura H, Watanabe M, et al. Clinicoelectrographic concordance between monozygotic twins with severe myoclonic epilepsy in infancy. Epilepsia 1990;31:2816.
  • 32
    Timmings PL, Richens A. Lamotrigine in primary generalized epilepsy. Lancet 1992;339:1300.
  • 33
    Gram L. Treatment of typical absences: acetazolamide, benzodiazepines and lamotrigine. In: DuncanJS, PanayiotopoulosCP, eds. Typical absences and related epileptic syndromes. London : Churchill Communications Europe, 1995:36875.
  • 34
    Dravet C. Controlled trials in nonprogressive myoclonic epilepsies. In: FejermanN, ChamolesNA, eds. New trends in pediatric neurology. Amsterdam : Excerpta Medica, 1993:2839.
  • 35
    Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:14879.
  • 36
    Carter Snead O, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:91621.
  • 37
    Guerrini R, Paglia G, Dravet C, et al. Efficacy of vigabatrin as add-on therapy in relation to type of epilepsy or epileptic syndrome: retrospective study of 120 patients. Epilepsia 1994;35 (suppl 7):65.